Quick Facts
FONT-SIZE Plus   Neg
Share SHARE
mail  E-MAIL

Foundation Medicine And Clovis Oncology Enter Into Diagnostic Collaboration

RELATED NEWS
Trade CLVS now with 
8/6/2012 7:23 AM ET

Foundation Medicine Inc. and Clovis Oncology Inc. (CLVS: Quote) announced that they have entered into a diagnostic collaboration. The company said that the goal of the collaboration is to develop an in-vitro diagnostic or IVD to identify biomarkers to select cancer patients most likely to respond to Clovis' product candidate rucaparib, a poly (ADP-ribose) polymerase or PARP inhibitor currently in Phase I/II clinical development.

Clovis Oncology said that the company and Foundation Medicine will analyze the genomic alterations found in tissue samples from patients to evaluate the feasibility of developing an IVD method to identify patients who have tumors more likely to respond to rucaparib.

In particular, the goal of the collaboration is to identify the additional genetic mutations beyond those in germ-line and somatic BRCA that are associated with defective DNA repair and may define appropriate tumor targets for rucaparib.

Click here to receive FREE breaking news email alerts for Clovis Oncology, Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
While Republicans will try to use the troubled rollout of Obamacare to their advantage in the upcoming midterm elections, the results of a Reuters/Ipsos poll showed that Americans increasingly think Democrats have a better plan for healthcare. Nearly three hundred people are still unaccounted for after a ferry carrying 462 people capsized and sank off South Korea's southern coast, media reports citing local officials said Wednesday. The ill-fated ferry, carrying mostly high school students on an overnight trip, was heading to the tourist island of Jeju from the city of Incheon, a northwestern South Korean city that houses the country's After moving mostly higher in early trading on Wednesday, stocks have continued to perform well over the course of the session. While buying interest has waned since then open, the markets have maintained a positive bias on the day.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.